Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 197

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

Open access
Alban, Tyler J., Alvarado, Alvaro G., Sorensen, Mia D., Bayik, Defne, Volovetz, Josephine, Serbinowski, Emily, Mulkearns-Hubert, Erin E., Sinyuk, Maksim, Hale, James S., Onzi, Giovana R., McGraw, Mary, Huang, Pengjing, Grabowski, Matthew M., Wathen, Connor A., Ahluwalia, Manmeet S., Radivoyevitch, Tomas, Kornblum, Harley I., Kristensen, Bjarne W., Vogelbaum, Michael A., Lathia, Justin D. · 2018 · JCI Insight

Abstract

Abstract/Summary Glioblastoma (GBM) remains uniformly lethal, and, despite a large accumulation of immune cells in the microenvironment, there is limited anti-tumor immune response, even with newly developed immune checkpoint therapies. To overcome these challenges and enhance the efficacy of immunotherapies, a comprehensive understanding of the immune system in GBM and changes during disease progression is required. Here, we integrated multi-parameter flow cytometry and mass cytometry time of flight (CyTOF) analysis of patient blood to determine changes in the immune system among tumor types and over disease progression. Utilizing multi-parameter flow cytometry analysis in a cohort of over 250 patients with brain tumors ranging from benign to malignant primary and metastatic, we found that GBM patients had a significant elevation in myeloid-derived suppressor cells (MDSCs) in blood, but not immunosuppressive T regulatory cells. We validated these findings in GBM patient tissue and found that increased numbers of MDSCs in recurrent GBM portended poor prognosis. CyTOF analysis of peripheral blood from a cohort of newly diagnosed GBM patients revealed that reduction in MDSC frequency over time is accompanied by a concomitant increase in dendritic cells and natural killer cells. This reduced MDSC profile was present in GBM patients with extended survival and was similar to that of low-grade glioma (LGG) patients. Our findings provide a rationale for developing strategies to target MDSCs, which are elevated in GBM patients and predict poor prognosis, either by directly targeting or by shifting the immune profile to induce differentiation toward the immune profile of LGGs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.122264

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 197

Metadata

Authors
Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E. E., Sinyuk, M., Hale, J. S., Onzi, G. R., McGraw, M., Huang, P., Grabowski, M. M., Wathen, C. A., Ahluwalia, M. S., Radivoyevitch, T., Kornblum, H. I., Kristensen, B. W., Vogelbaum, M. A., & Lathia, J. D.
Venue
JCI Insight
Published
2018-11-02
Volume
3
Issue
21
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2896013175
Cited by
197
References
8
FWCI
10.06
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. https://app.cochat.ai/papers/10.1172/jci.insight.122264
The paper
Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E. E., Sinyuk, M., Hale, J. S., Onzi, G. R., McGraw, M., Huang, P., Grabowski, M. M., Wathen, C. A., Ahluwalia, M. S., Radivoyevitch, T., Kornblum, H. I., Kristensen, B. W., Vogelbaum, M. A., & Lathia, J. D. (2018). Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. https://doi.org/10.1172/jci.insight.122264

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.